Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions

被引:6
|
作者
Bais, Preeti [1 ]
Beebe, Kirk [2 ]
Morelli, Kathryn H. [1 ,3 ]
Currie, Meagan E. [1 ]
Norberg, Sara N. [1 ]
Evsikov, Alexei V. [1 ,4 ]
Miers, Kathy E. [1 ]
Seburn, Kevin L. [1 ]
Guergueltcheva, Velina [5 ,9 ]
Kremensky, Ivo [6 ]
Jordanova, Albena [7 ,8 ]
Bult, Carol J. [1 ]
Burgess, Robert W. [1 ,3 ]
机构
[1] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA
[2] Metabolon Inc, Durham, NC 27713 USA
[3] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA
[4] Univ S Florida, Dept Mol Med, USF Hlth, Tampa, FL 33620 USA
[5] Med Univ Sofia, Dept Neurol, Sofia 1431, Bulgaria
[6] Med Univ Sofia, Univ Hosp Obstet & Gynecol, Dept Obstet & Gynecol, Natl Genet Lab, Sofia 1431, Bulgaria
[7] Univ Antwerp, VIB Dept Mol Genet, Mol Neurogen Grp, B-2610 Antwerp, Belgium
[8] Med Univ Sofia, Dept Med Chem & Biochem, Mol Med Ctr, Sofia 1431, Bulgaria
[9] Univ Hosp Sofiamed, Sofia 1797, Bulgaria
来源
Biology Open | 2016年 / 5卷 / 07期
基金
美国国家卫生研究院;
关键词
Peripheral neuropathy; Spinal cord; Sciatic nerve; Metabolomics; Mass Spectrometry; tRNA synthetase; TRANSFER-RNA SYNTHETASE; ACETYL-L-CARNITINE; ASCORBIC-ACID TREATMENT; SPINAL MUSCULAR-ATROPHY; ALPHA-LIPOIC ACID; OLD RATS; PERIPHERAL NEUROPATHY; SERINE PALMITOYLTRANSFERASE; MASS-SPECTROMETRY; METABOLOMICS DATA;
D O I
10.1242/bio.019273
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Charcot-Marie-Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot-Marie-Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite 'fingerprint' we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.
引用
收藏
页码:908 / 920
页数:13
相关论文
共 50 条
  • [31] A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients
    Wang, Wenjia
    Guedj, Mickael
    Bertrand, Viviane
    Foucquier, Julie
    Jouve, Elisabeth
    Commenges, Daniel
    Proust-Lima, Cecile
    Murphy, Niall P.
    Blin, Olivier
    Magy, Laurent
    Cohen, Daniel
    Attarian, Shahram
    PLOS ONE, 2017, 12 (01):
  • [32] Charcot-Marie-Tooth disease: Emerging mechanisms and therapies
    d'Ydewalle, Constantin
    Benoy, Veronick
    Van den Bosch, Ludo
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2012, 44 (08): : 1299 - 1304
  • [33] Anaesthetic implications in patient with Charcot-Marie-Tooth disease
    Kapoor, Hemlata
    Shah, Milin
    Desai, Suhani
    INDIAN JOURNAL OF ANAESTHESIA, 2021, 65 (07) : 561 - 562
  • [34] Disease course of Charcot-Marie-Tooth disease type 2 and comorbidity
    Gemignani, F
    Marbini, A
    ARCHIVES OF NEUROLOGY, 2004, 61 (09) : 1470 - 1470
  • [35] Dynamin 2 in Charcot-Marie-Tooth Disease
    Tanabe, Kenji
    Takei, Kohji
    ACTA MEDICA OKAYAMA, 2012, 66 (03) : 183 - 190
  • [36] Utility of Charcot-Marie-Tooth Neuropathy Score in Children With Type 1A Disease
    Haberlova, Jana
    Seeman, Pavel
    PEDIATRIC NEUROLOGY, 2010, 43 (06) : 407 - 410
  • [37] CHARCOT-MARIE-TOOTH DISEASE TYPE-1
    MALCOLM, S
    JOURNAL OF MEDICAL GENETICS, 1992, 29 (01) : 3 - 4
  • [38] CHARCOT-MARIE-TOOTH DISEASE TYPE I IN RUSSIA
    Milovidova, T.
    Schagina, O.
    Dadali, E.
    Fedotov, V.
    Polyakov, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 656 - 656
  • [39] Reversible inflammatory neuropathy superimposed on Charcot-Marie-Tooth type 1A disease
    José Gazulla
    Carmen Almárcegui
    José Berciano
    Neurological Sciences, 2018, 39 : 793 - 794
  • [40] Reversible inflammatory neuropathy superimposed on Charcot-Marie-Tooth type 1A disease
    Gazulla, Jose
    Almarcegui, Carmen
    Berciano, Jose
    NEUROLOGICAL SCIENCES, 2018, 39 (04) : 793 - 794